Longevity Science • Category 17 · New

The FDA reopens the door to 6 peptides it had closed in 2023.

BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax are back on the FDA's table. An advisory committee voted in favor of adding them back to the list of substances specialty pharmacies can use under a doctor's prescription — the same type of list the FDA had removed several of them from in 2023. Here's what the research reports on each, and the five quality controls that separate a serious peptide from an improvised one.

From banned in 2023 to reconsidered in 2025

In 2023, the FDA removed several popular peptides — including BPC-157 — from the 503A list, the list of substances compounding pharmacies can use to prepare customized medications under prescription. At the time, it was a signal of regulatory caution.

Two years later, the FDA's own Pharmacy Compounding Advisory Committee voted — narrowly, but in favor — to add six peptides back to that list: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. It's the first formal signal, from inside the U.S. regulatory system itself, that the growing body of scientific literature and documented clinical use is shifting the conversation.

It's not drug approval. It is, however, the door that was closed in 2023 — reopened for discussion in 2025.
Ch. 02 · The six peptides on the table

What each one is, and what research reports

Reported benefits and researched uses for each peptide — preclinical and observational literature and, in some cases, documented clinical use outside the United States.

  • BPC-157

    Tissue repair

    A pentadecapeptide derived from a protective gastric protein. Researched for its role in gastrointestinal, tendon, ligament and muscle repair, and for angiogenic and anti-inflammatory properties. Documented clinical use in Croatia.

  • KPV

    Anti-inflammatory

    A tripeptide derived from alpha-MSH. Researched for anti-inflammatory and antimicrobial properties, particularly in models of intestinal inflammation and inflammatory skin conditions.

  • TB-500 (Thymosin Beta-4)

    Regeneration and healing

    A synthetic fragment of Thymosin Beta-4, a naturally occurring actin-regulating protein. Researched for its role in wound healing, muscle and cardiac repair, and promotion of angiogenesis.

  • MOTS-c

    Mitochondrial metabolism

    A peptide derived from mitochondrial DNA, discovered through translational research at USC. Studied for its role in metabolic regulation, AMPK activation, insulin sensitivity, and as a potential exercise mimetic.

  • Epitalon

    Cellular senescence

    A synthetic tetrapeptide researched for decades by Vladimir Khavinson (St. Petersburg). Studied for its proposed effect on telomerase activity, pineal gland regulation, and cellular senescence.

  • Semax

    Cognition and neuroprotection

    A synthetic heptapeptide derived from an ACTH fragment, developed in Russia. Researched for nootropic and neuroprotective effects and its ability to increase BDNF expression. Approved in Russia for specific neurological indications.

The five quality controls every peptide must have

A peptide isn't just its molecule — it's also the process that manufactures, purifies and verifies it. One of the risks the FDA itself cited to justify caution is batch-to-batch quality variability. These are the five documents that separate a serious peptide from one manufactured without traceability.

  • 01 · Endotoxin testing

    LAL test

    The Limulus Amebocyte Lysate (LAL) test detects residual bacterial endotoxins left over from the synthesis process. A peptide without this control can trigger severe febrile or inflammatory reactions upon administration.

  • 02 · Microbiological panel

    Sterility and bioburden

    Verifies the absence of bacterial and fungal contamination. It's the basic sterility control any injectable product must pass before being considered fit for use.

  • 03 · Heavy metals

    Lead · mercury · arsenic · cadmium

    Peptide synthesis can leave traces of metal catalysts. A heavy metals panel confirms those residues fall below recognized safety limits.

  • 04 · Certificate of Analysis (CoA)

    Batch-specific, not generic

    A document issued by the manufacturer for that specific batch, not a generic product certificate. It must include the actual test results for all quality checks on that particular batch.

  • 05 · Certificate of purity

    HPLC · mass spectrometry

    Confirms what percentage of the content is actually the stated peptide — ideally above 98% — and not degraded fragments, incorrect isomers, or entirely different compounds.

Synthesis

The 2025 vote doesn't turn these peptides into approved medications. It turns a conversation that seemed closed in 2023 into one that's open again today — and for a field moving faster than regulation, that's a signal worth following closely.

What doesn't change with any vote is the quality bar: endotoxins, microbiology, heavy metals, certificate of analysis, and certificate of purity. That bar applies always — before, during and after any regulatory decision.

For the full picture, here's what the vote means — and what it doesn't

The body that voted is the FDA's Pharmacy Compounding Advisory Committee (PCAC) — not the agency itself, and its role is to advise, not decide. It voted on whether these peptides should be eligible for the 503A list, which allows compounding pharmacies to prepare them under an individual prescription. This is not drug approval: compounded products don't go through the same review process, safety labeling, or post-market surveillance as a drug approved through the FDA's standard pathway.

The vote was narrow, and the FDA's own staff scientists unanimously opposed it, citing insufficient clinical data. It's also worth noting that six of the eight committee members run clinics that offer peptides — a conflict of interest that's been publicly flagged. A seventh peptide reviewed, emideltide, was rejected for insufficient evidence. The outcome, ultimately, is non-binding: it requires final FDA sign-off, which may take time or may not happen at all.

We tell the positive part because it's real. We tell this part because it's real too — a serious clinic doesn't get to pick which half of the story to tell.

This content is an editorial review of a regulatory development of public interest, not an offer to sell or administer these peptides. In Colombia, none of these peptides has INVIMA approval for general therapeutic use; the FDA's regulatory process in the United States does not change Colombia's regulatory framework.

Frequently asked questions about the FDA's vote and these 6 peptides

The questions we hear most often when explaining what this regulatory development actually means.

01

Did the FDA approve BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax?

No. What happened was a vote by the FDA's Pharmacy Compounding Advisory Committee (PCAC), recommending these 6 peptides be added to the 503A list — the list of substances compounding pharmacies can use to prepare customized medications under a doctor's prescription.

The vote was narrow, is non-binding, and requires final FDA sign-off. It is not equivalent to drug approval.

02

Why is this good news if it isn't formal approval?

Because it represents a reversal. The FDA had removed BPC-157 from the 503A list in 2023 over safety concerns. An advisory committee now voting to add several of these peptides back signals that the regulatory consensus is actively reconsidering their risk-benefit profile.

03

What benefits does research report for these peptides?

They vary by peptide: BPC-157 and TB-500 are researched for gastrointestinal, tendon and muscle repair; KPV for intestinal and skin anti-inflammatory properties; MOTS-c for metabolic regulation and insulin sensitivity; Epitalon for its proposed effect on telomerase and cellular senescence; Semax for nootropic and neuroprotective effects.

04

Are these peptides available in Colombia?

Colombia's INVIMA regulatory framework is independent of the FDA process in the United States. None of these peptides has INVIMA approval for general therapeutic use in Colombia. The U.S. advisory committee vote does not change Colombia's regulatory status.

05

What quality controls should a peptide have before it's considered safe?

At minimum five: an endotoxin test (LAL), a microbiological panel, heavy metals analysis, a batch-specific certificate of analysis (CoA), and a certificate of purity via HPLC or mass spectrometry. Without these five documents, there is no way to verify what a peptide actually contains.

06

Does Wellness Care sell or administer these peptides?

This page is editorial, educational content about a regulatory development of public interest — it is not an offer to sell or administer these peptides. Any therapeutic consideration is framed within applicable regulation and individual medical judgment.

07

What happened to emideltide, the seventh peptide reviewed?

The committee rejected it, citing insufficient evidence. It's a reminder that the committee's process isn't a formality — some peptides, given the evidence presented, didn't clear the bar.

Want to understand which peptides apply to your case?

Review the full state of the art in therapeutic peptides

Our peptide library organizes the global regulatory status into three layers — approved, in active research, and preliminary evidence — so you understand exactly where each compound stands today. Whatever we decide to do with that information is always an individual clinical conversation.

View the full peptide library